... polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers ... NIAID.
One unique design underlying this combination HIV vaccine formulation is the use of a “cocktail” of five different ...
... of the National Institutes of Health (NIH), is reshaping its research enterprise to broaden HIV vaccine discovery activities. Many of the initiatives have evolved from ideas and opinions recently ...
Failure to find an HIV vaccine candidate should not mean shutting down clinical trial centres in Africa, say researchers.
... lymphoid tissue, or both.
The authors conclude with cautious optimism that an effective HIV vaccine will be developed, but will depend on the significant growth of scientific understanding of HIV ...
... infections with adenoviruses—may have altered the immune response to the HIV vaccine. In the presence of antibodies from Ad5-immune ... turn to activate T cells. Since HIV prefers to infect active T cells ...
... many investigators and thousands of study participants for their contribution to the search for an effective HIV vaccine."
"As disappointing as the outcome of the Step study was, we will continue ...
... , UK to test a prime-boost combination of two HIV vaccine candidates. The news follows promising results for one of the two vaccine candidates to be tested, the MVA-based TBC-M4, which ...
... Laboratory of Molecular Immunology, suggests that an effective HIV vaccine may come from a shotgun approach using of a wide ... should look like."
HIV strains mutate rapidly, making them especially wily ...
... years, researchers have tried and failed to develop an HIV vaccine, primarily by focusing on a small number ... diverse team of antibodies in 'slow-progressing' HIV patients whose coordinated pack hunting ...
... occurring, broadly neutralizing anti-HIV antibodies for the ultimate design of an antibody-based HIV vaccine.
Key aspects of this strategy include
Obtaining new broadly neutralizing antibodies ...
... an explanation for this increased susceptibility to infection remains a major focus for HIV vaccine researchers.
These individuals were found to have high blood Ad5 neutralizing antibody (nAb) ...
Africa's first home-grown HIV vaccines have started early-stage clinical trials in South Africa and the United States.
... Consequently, the antibodies inactivate HIV effectively," Paul said.
"The failure of previous HIV vaccine trials has produced pessimism about the prospect of effective HIV vaccination. Our approach ...
... infection, but certainly this is an encouraging advance for the HIV vaccine field.
"We thank the trial staff in Thailand ... 3 and 6 months. Participants were tested for HIV infection every 6 months for 3 ...
... deal with. Alright, somebody go
cook up a vaccine: problem solved". According to wikipedia, senior figures ... Continue
reading for a brief analysis of the latest HIV vaccine study: even
better
continue ...
